Publications by authors named "R Smallridge"
BRAFV600E/pTERT double mutated papillary thyroid cancers exhibit immune gene suppression.
Front Endocrinol (Lausanne)
December 2024
Introduction: BRAFV600E mutation (BRAF) is common in papillary thyroid cancer (PTC), and most patients have an excellent outcome. However, a TERT-promoter mutation (pTERT) in the presence of BRAF (BRAFpTERT) has been demonstrated to confer a more aggressive behavior to PTC. Lymphocytic infiltration is often present in PTC.
View Article and Find Full Text PDFArticle Synopsis
- Anaplastic thyroid carcinoma is one of the deadliest cancers and frequently occurs alongside differentiated thyroid cancers, but its aggressive nature is not well understood.
- Researchers analyzed tumor DNA from 329 regions of thyroid cancer, revealing that anaplastic thyroid carcinomas have more mutations and unique mutational patterns compared to other thyroid cancers.
- The study shows that although anaplastic and differentiated thyroid carcinomas can occur in the same patient, they have different mutated genes and share a common genetic origin that allows them to develop from a similar malignant environment.
Introduction: Anaplastic thyroid cancer (ATC) is one of the most lethal diseases known to humans with a median survival of 5 months. The American Thyroid Association (ATA) recently published guidelines for the treatment of this dreadful thyroid malignancy.
Areas Covered: This review presents the current therapeutic landscape of this challenging disease.
Anaplastic thyroid cancer (ATC) is one of the most lethal of all cancers. It is more common in women and occurs primarily in older patients. ATC has a median overall survival of 3-5 months and a nearly 100% disease-specific mortality.
View Article and Find Full Text PDFPurpose: To compare cardiovascular outcomes and rates of fractures and falls among patients with persistent brand-name versus generic L-thyroxine use.
Methods: Retrospective, 1:1 propensity-matched longitudinal study using a national administrative claims database to examine adults (≥18 years) who initiated either brand or generic L-thyroxine between 2008 and 2018, censored at switch or discontinuation of L-thyroxine formulation or disenrollment from the health plan. Main outcome measures included rates of hospitalization for atrial fibrillation, myocardial infarction, congestive heart failure, stroke, spine and hip fractures, and rate of falls in the outpatient or inpatient setting.